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day). Overall, the cost was $466 (SD  $1361)/woman ($2.59/woman/day), with 
productivity loss accounting for 40% of the total, physician visits for 21% and medi-
cations for 11.6%. Statistically signiﬁcant differences were found between pre- and 
perimenopause (P  0.003) and between pre- and post-menopause (P  0.01). CON-
CLUSIONS: This observational study was based on data reported by women 48–54 
years of age, presenting at primary care practices in Canada. Perimenopause was the 
period with the highest burden. The major limitation was recall by subjects but the 
recall period was limited to a usually acceptable 6-month timeframe.
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OBJECTIVES: Pre-menstrual dysphoric disorder (PMDD) is a severe form of Pre-
menstrual Syndrome (PMS). Limited data exist to quantify the burden of PMDD on 
individual women and society, especially in a European setting. To investigate the 
relationship between symptom severity, cost and impairment in women with moder-
ate/severe PMS or PMDD. METHODS: A model was constructed to quantify costs 
and impairment, based on analysis of a cross-sectional dataset. Heterogeneity was 
assessed and data included from 9 OECD countries. Analyses were reported applying 
Swedish cost from a societal perspective to the cross-sectional dataset. Data were 
analysed according to categories of symptom severity based on the DRSP total luteal 
symptom score. Five severity categories were deﬁned: Category 1 comprised women 
with DRSP scores 21–41.9, Category 2, 42–62.9, Category 3, 63–83.9, Category 4, 
84–104.9, and Category 5 scores of 105. The output of the analysis was an estimate 
of mean annual cost and impact on quality of life (measured by utility) by category. 
Conﬁdence intervals were generated through non-parametric bootstrapping. 
RESULTS: A total of 756 women were included in the analysis, 225 provided data 
on quality of life. Total annual costs (direct and indirect) were estimated at: SEK 8894 
(95% CI 7137, 10,745), SEK 14,393 (95% CI 11,629, 17,505), SEK 24,178 (95% 
CI 17,961, 30,819), SEK 23,809 (95% CI 12,740, 40,144) and SEK 48,201 (95% CI 
26,103, 75,635) for categories 1 to 5 respectively; utility at 0.81 (95% CI 0.78, 0.84), 
0.72 (95% CI 0.67, 0.76), 0.71 (95% CI 0.64, 0.77), 0.63 (95% CI 0.47, 0.76) and 
0.78 (95% CI 0.70, 0.93). CONCLUSIONS: Our analysis, modeled from a Swedish 
societal perspective, found a substantial burden associated with moderate/severe PMS 
and PMDD increasing with severity of symptoms. Further quantiﬁcation of the mon-
etary impact and research into geographical interactions is needed to better understand 
the burden of PMDD.
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OBJECTIVES: Cytomegalovirus (CMV) can be transmitted to a developing child 
during pregnancy. In Germany, seropositivity rate is around 50%, risk of seroconver-
sion during pregnancy 1% and congenital infection resulting from primary infection 
about 50%. Every year 495 infants will be born with congenital CMV-syndrome and 
186 infants are infected but asymptomatic at birth and will develop a multitude of 
abnormalities (hearing loss, mental retardation etc.) due to primary CMV infection 
just as well as 750 children from seropositive mothers. The disease burden for affected 
children and parents is enormous. METHODS: The objective of this study was to 
estimate the total economic impact (lifetime direct and indirect costs based on deliver-
ies p.a.) on society due to CMV-infection based on incidences. Additionally this study 
shows the positive monetary impact of screening (serologic testing and treatment in 
case of primary infection). Direct costs comprise all treatment costs of symptoms 
appearing at birth or later on. The incidences of sequelae were derived from literature. 
Indirect costs comprise the changed job situation of parents, work absenteeism, 
nursing leave, lost human capital of dead people, costs of special schools and nursing 
homes. The resource use was determined by literature and experts. All costs represent 
data from 2008. RESULTS: The total discounted costs of CMV infection from a 
societal perspective were a243m p.a. (941ma undiscounted), whereas a225m p.a. 
(a870m undiscounted) are indirect costs corresponding to a766,444 per child (a2.97m 
undiscounted). Total costs for diagnosis and prevention are a50.43m. CMV screening 
and treatment of primary infected mothers by CMV speciﬁc hyperimmunoglobulin 
reduce total societal costs to a152ma (a444m undiscounted) and prevents infection in 
640 children. The budget impact amounts to a91m (a497m undiscounted). CONCLU-
SIONS: CMV-infection causes high disease burden and costs. A screening program is 
suitable to decrease future costs and disease burden of affected infants and parents.
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OBJECTIVES: Postmenopausal osteoporosis (PMO) increases the risk of fractures. 
However, studies have shown that only 20% of German osteoporosis patients receive 
osteoporosis-speciﬁc therapy and for many the adherence to medication is poor. This 
study assessed the economic burden of PMO in Germany. METHODS: We applied a 
systematic review of literature utilizing German based data to quantify osteoporosis-
related costs. Our analysis considered both direct costs (inpatient care with/without 
fracture, rehabilitation, medication, nursing care) and indirect costs (absence from 
work, early retirement and mortality) attributable to PMO. RESULTS: We identiﬁed 
and analyzed eight cost studies and two administrative databases published between 
1999 and 2009. Administrative data sources revealed annual direct and indirect costs 
of PMO amounting to a2205 million (direct costs: a1697–1879 million). Direct inpa-
tient costs resulting from osteoporosis-related fracture are three times higher than 
osteoporosis without fracture. Mean hip fracture costs were a7,109–a12,526 and 
mean costs of vertebral fractures were a4400–a6171. Ambulatory nursing care results 
in about a132 million per year. Annual inpatient rehabilitation costs add up to a147 
million. Annual costs of medication range between a338 million and a664 million. 
Annual indirect costs due to sickness absence were calculated at a146 million early 
retirement at a144 million and early death at a34 million. CONCLUSIONS: PMO 
currently has a considerable economic impact on the German health care system, 
which will increase with projected demographic changes. Strategies should be aimed 
at improving the management of this disease.
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OBJECTIVES: As the goals of in-vitro fertilization (IVF) treatments are to deliver a 
healthy child, where even a twin pregnancy is regarded as an adverse outcome, the 
economic impact of multiple births is an important policy consideration. METHODS: 
We estimated the potential cost savings by reducing the number of multiple pregnan-
cies and births in Canada over the next ﬁve years. The direct medical costs included 
clinical management costs of singleton, twin and higher order multiple (HOM) preg-
nancies, hospital delivery costs of mothers and their offspring by multiple birth, term 
and pre-term birth and the costs of disabilities due to pre-term/low weight birth. The 
analysis was conducted from the perspective of a third party payer in Canada. All 
parameters were based on recently published literature. The results were expressed as 
age-speciﬁc incremental costs per live birth. RESULTS: Given the reductions in mul-
tiple birth rate equivalent to those reached recently by selected European countries, 
we estimated that, over the next ﬁve years in Canada, the proportions of singletons, 
twins and HOM could be reduced from 71.2%, 27.5% and 1.3% to 86.6%, 12.8% 
and 0.6%, respectively. The potential cost savings are estimated to reach $266 million. 
The over-all incremental cost per live birth could be reduced by $15,228. For women 
under 35, aged 35–39, and over 40, the incremental cost reductions would be $17,023, 
$13,860 and $10,749, respectively. The bulk of cost reductions (over 70%) would be 
attributable to reductions in disability costs related with preterm/low weight births. 
Extensive sensitivity analysis has been provided. CONCLUSIONS: In the context of 
limited resources and ever-expanding need for health care services, prudent policies 
regarding multiple birth reductions are highly desirable.
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OBJECTIVES: With increasing numbers of termination of pregnancies in Scotland, 
offering a broader range of contraceptive options can increase the number of women 
satisﬁed with their method, leading to reduced discontinuation and the resulting posi-
tive consequences. This study aimed at assessing the cost-effectiveness of the etono-
gestrel (ENG)/ethinyl estradiol (EE) vaginal ring from the Scottish National Health 
Service (NHS) perspective. METHODS: A decision-analytic model was constructed to 
estimate the relative cost-effectiveness of the ENG/EE vaginal ring and a weighted, 
average second-line method (including the transdermal patch, long-acting methods, 
barrier and natural methods) following the use of oral contraceptives. Effectiveness 
data were derived from a systematic literature review and clinical trials for the vaginal 
ring. Costs were based on UK National sources. RESULTS: Versus a weighted, average 
second-line method, the vaginal ring cost an additional GBP£53 per woman and 
reduced the rate of unintended pregnancy by 0.0158. The incremental cost-effective-
ness ratio (ICER) of the vaginal ring versus a weighted, average second-line method 
was GBP£3337 per pregnancy averted. This ICER can be viewed as a conservative 
estimate as this study only assessed the weighted cost per pregnancy and was unable 
to address the psychological and physical implications which may result from an 
unintended pregnancy. Discontinuation and failure rates were a key determinant of 
the cost-effectiveness of the vaginal ring. CONCLUSIONS: Whilst the vaginal ring is 
more effective and more costly than a weighted, average second-line method from the 
Scottish NHS perspective, a lack of information surrounding indirect costs, compli-
ance impact and health state utilities warrants further analysis to determine the full 
cost implications. Collection of quality of life data for unintended pregnancies could 
assist in deriving an appropriate cost-effectiveness threshold.
